The biology of chronic pain
Chronic pain is not simply persistent acute pain — it involves distinct mechanisms:
- Peripheral sensitisation:Inflammatory mediators (prostaglandins, bradykinin, substance P) reduce the activation threshold of peripheral nociceptors (pain-sensing nerve endings). COX-2-derived PGE2 is the primary sensitising prostaglandin — the mechanism targeted by NSAIDs.
- Central sensitisation:Repeated nociceptive input causes wind-up in spinal cord dorsal horn neurons — they become hyper-responsive, so normal stimuli become painful (allodynia) and mildly painful stimuli become severely painful (hyperalgesia). NF-κB drives central sensitisation in spinal cord glial cells.
- Neuroinflammation:Microglial activation in the brain and spinal cord — sustained by NF-κB and NADPH oxidase — perpetuates the central pain state. This mechanism overlaps with fibromyalgia, chronic widespread pain, and central sensitisation syndromes.
Spirulina’s anti-pain mechanisms
COX-2 inhibition (peripheral)
Phycocyanin inhibits COX-2 — the enzyme that produces PGE2 (peripheral sensitising prostaglandin) and PGI2. This is the same mechanism as ibuprofen and celecoxib, though at lower potency. Animal pain models (acetic acid writhing, hot plate test, carrageenan paw oedema) consistently show phycocyanin reduces pain responses — effects partially blocked by COX-2 inhibitors, confirming the mechanism.
NF-κB inhibition (central and peripheral)
NF-κB is required for COX-2 expression, TNF-α and IL-1β production, and central sensitisation in spinal cord glial cells. Phycocyanobilin’s NADPH oxidase inhibition reduces the ROS that maintain NF-κB in an active state — addressing both peripheral and central components of chronic pain.
GLA and eicosanoid balance
Spirulina’s GLA generates DGLA, which is converted to anti-inflammatory PGE1 — competing with the pro-inflammatory arachidonic acid pathway. This shifts the eicosanoid balance away from PGE2 and toward PGE1 over weeks of supplementation.
Pain conditions and spirulina: a condition-specific view
Inflammatory arthritis pain (RA, psoriatic arthritis)
The most mechanistically well-matched application. Joint inflammation involves synovial NF-κB and COX-2 activation — exactly the targets of phycocyanin. However, RA requires DMARDs and specialist management; spirulina is at best an adjunct, and immune stimulation effects require rheumatologist discussion.
Osteoarthritis pain
OA involves both mechanical damage and low-grade synovial inflammation. NF-κB drives IL-1β and MMP expression in OA cartilage. Spirulina’s NF-κB inhibition is relevant to the inflammatory component — not to the mechanical and structural damage. As an adjunct for OA joint pain, it is mechanistically reasonable.
Fibromyalgia and central sensitisation
Central sensitisation syndromes (fibromyalgia, chronic widespread pain, tension-type headache, IBS) all have microglial NF-κB and NADPH oxidase activation as a shared mechanism. Phycocyanobilin is the compound most specifically targeting this pathway — a small fibromyalgia pilot (Paithoonrangsarid et al., 6 g/day) showed fatigue improvement consistent with the central mechanism.
Neuropathic pain
Neuropathic pain (from nerve damage, diabetes, post-herpetic neuralgia) involves neuroinflammation and microglial activation. Phycocyanobilin crosses the blood-brain barrier and inhibits microglial NADPH oxidase — the strongest mechanistic case for spirulina in neuropathic pain. Human trial evidence is absent, but animal neuropathic pain models show phycocyanin reduces mechanical allodynia.
Cancer pain
Cancer pain management requires specialist oncology input. Spirulina is not appropriate for self-managing cancer pain — any supplement must be discussed with the oncology team.
What spirulina doesn’t replace for chronic pain
- NSAIDs and analgesics:For moderate-to-severe inflammatory pain, spirulina does not approach the analgesic potency of NSAIDs. It is a complementary anti-inflammatory, not a replacement.
- Physiotherapy and movement:Exercise is the most evidence-supported intervention for most chronic pain conditions. Spirulina addresses inflammation; it cannot address deconditioning, movement patterns, or psychological components of pain.
- Pain psychology:Central sensitisation has strong psychological modulation — CBT for chronic pain is more effective than any supplement.
Dosing for anti-inflammatory pain support
- Target dose:5–8 g/day for meaningful phycocyanin delivery. Anti-inflammatory trials generally use ≥4 g/day.
- Timeline: Anti-inflammatory effects require 4–8 weeks of consistent use to become clinically apparent. Pain reduction, if it occurs, is gradual — not immediate.
- Monitoring:If on NSAIDs long-term, spirulina’s COX-2 inhibition is additive but the interaction at standard supplement doses is not clinically significant for most patients.